StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) stock

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.88−0.08 (-8.24%)

Close on Nov 16, 2026Market cap $13.93MP/E –Yield –

Allarity Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Allarity Therapeutics's ebitda for the twelve months ending Jun 30, 2025 was -$26.77M. For fiscal 2024 it was -$27.23M. The highest annual figure on record is -$8.27M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$27.23M–
FY2023Dec 31, 2023-$17.09M–
FY2022Dec 31, 2022-$34.40M–
FY2021Dec 31, 2021-$26.45M–
FY2020Dec 31, 2020-$8.27M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-$4.12M–
Q1 FY2025Mar 31, 2025-$3.03M–
Q4 FY2024Dec 31, 2024-$7.32M–
Q3 FY2024Sep 30, 2024-$12.31M–
Q2 FY2024Jun 30, 2024-$3.37M–
Q1 FY2024Mar 31, 2024-$4.24M–
Q4 FY2023Dec 31, 2023-$4.87M–
Q3 FY2023Sep 30, 2023-$4.42M–
Q4 FY2022Dec 31, 2022-$6.75M–
Q3 FY2022Sep 30, 2022-$4.55M–
Q2 FY2022Jun 30, 2022-$4.82M–
Q1 FY2022Mar 31, 2022-$18.29M–
Q4 FY2021Dec 31, 2021-$15.73M–
Q3 FY2021Sep 30, 2021-$3.94M–
Q2 FY2021Jun 30, 2021-$4.38M–
Q1 FY2021Mar 31, 2021-$2.41M–
Q4 FY2020Dec 31, 2020-$2.59M–

More Allarity Therapeutics figures

See a number that looks wrong?